Agency officials promise fast reviews of new treatments while vowing they will not be a “rubber stamp” for the industry. But patients with rare diseases view recent decisions as signs that the doors are closing on their options.
Več na: https://www.nytimes.com/2026/03/05/health/fda-drugs-rare-diseases-rfk-jr.html